Azelis Group NV (AZLGF)
| Market Cap | 3.02B -20.0% |
| Revenue (ttm) | 4.83B -2.5% |
| Net Income | 130.55M -38.5% |
| EPS | 0.54 -38.3% |
| Shares Out | n/a |
| PE Ratio | 23.12 |
| Forward PE | 13.58 |
| Dividend | 0.26 (2.08%) |
| Ex-Dividend Date | Jun 27, 2025 |
| Volume | 400 |
| Average Volume | 6,757 |
| Open | 12.68 |
| Previous Close | 12.68 |
| Day's Range | 12.68 - 12.68 |
| 52-Week Range | 8.75 - 16.35 |
| Beta | 0.53 |
| RSI | 57.84 |
| Earnings Date | Jul 30, 2026 |
About Azelis Group NV
Azelis Group NV engages in the distribution of specialty chemicals and food ingredients. The company provides specialty chemical products used in the life sciences, such as personal care, home care, industrial cleaning, pharmaceuticals, healthcare, food and nutrition, animal nutrition, agricultural environmental, flavours and fragrances, and nutraceuticals solutions; and industrial chemicals industry, including CASE, advanced materials and additives, lubricants, metalworking fluids, electronics, essential and fine chemicals, textiles, leather, ... [Read more]
Financial Performance
In 2025, Azelis Group NV's revenue was 4.11 billion, a decrease of -2.45% compared to the previous year's 4.21 billion. Earnings were 111.19 million, a decrease of -38.46%.
Financial numbers in EUR Financial StatementsNews
Azelis Group NV Earnings Call Transcript: Q1 2026
Q1 2026 delivered stable revenue and strong cash generation despite ongoing market volatility and regional disparities. Cost discipline, strategic programs, and working capital efficiency supported performance, while supply chain risks and price inflation remain key uncertainties.
Azelis Group NV: Q1 2026 Results: Strong Cash Generation in Volatile Markets
ANTWERP, Belgium--(BUSINESS WIRE)--Regulatory News: Azelis Group NV (Brussels:AZE): Highlights Q1 2026 Revenue of EUR 1.0bn, down 0.7% year-on-year in constant currency (-5.2% reported), reflecting a ...
Azelis price target lowered to EUR 15 from EUR 17.50 at Goldman Sachs
Goldman Sachs analyst Suhasini Varanasi lowered the firm’s price target on Azelis (AZLGF) to EUR 15 from EUR 17.50 and keeps a Buy rating on the shares. Published first on…
Azelis price target raised to EUR 10.50 from EUR 10 at Barclays
Barclays analyst Gaurav Jain raised the firm’s price target on Azelis (AZLGF) to EUR 10.50 from EUR 10 and keeps an Equal Weight rating on the shares. Published first on…
Azelis Group NV Earnings Call Transcript: H2 2025
Revenue grew 1.3% year-over-year to EUR 4.1 billion, driven by acquisitions and resilient cash flow, despite softer demand and margin contraction. Net profit declined 37.6% to EUR 113 million, with strong free cash flow supporting stable leverage and ongoing strategic investments.
Azelis downgraded to Reduce from Hold at Kepler Cheuvreux
Kepler Cheuvreux downgraded Azelis (AZLGF) to Reduce from Hold with a price target of EUR 7.50, down from EUR 14. The firm sees an unfavorable risk/reward given the company’s leverage.
Azelis price target lowered to EUR 14.50 from EUR 16 at Deutsche Bank
Deutsche Bank analyst Tristan Lamotte lowered the firm’s price target on Azelis (AZLGF) to EUR 14.50 from EUR 16 and keeps a Buy rating on the shares. Published first on…
Azelis Group NV Earnings Call Transcript: Q3 2025
Revenue grew 2.1% year-on-year to EUR 3.2 billion, but margins contracted due to mix and regional pressures. Free cash flow rose 34% as cost savings ramped up, while leverage increased to 3.4x. Market volatility persists, but long-term fundamentals and M&A pipeline remain strong.
Azelis Group NV Earnings Call Transcript: H1 2025
Revenue grew 3.3% at constant currency in H1 2025, with EMEA offsetting U.S. and APAC weakness. Margins contracted due to mix and cost inflation, but strong cash flow and disciplined cost management support resilience. Cost savings and portfolio optimization to drive H2 improvement.
Azelis Group NV Earnings Call Transcript: Q1 2025
Q1 saw 4.5% revenue growth, but margin pressure from slower-than-expected organic growth and increased costs. Volatility, especially from new tariffs, led to cost-saving measures and cautious outlook, with positive organic growth expected but at a slower pace.
Azelis Group NV Earnings Call Transcript: H2 2024
Revenue grew 2.6% in constant currency to EUR 4.2 billion, with gross profit and EBITDA margins stable despite cost inflation. Eight acquisitions and portfolio optimization supported growth, while working capital and leverage rose due to inventory build for anticipated demand.
Azelis Group NV Earnings Call Transcript: Q3 2024
Organic revenue growth returned in Q3 2024, driven by recovery in key segments and strong performance in life sciences. Despite ongoing market volatility and higher leverage, the group remains optimistic for continued growth, supported by disciplined M&A and robust cash flow.
Azelis Group NV Earnings Call Transcript: H1 2024
Revenue and gross profit grew modestly in H1 2024, with strong conversion margins and continued M&A activity supporting resilience amid ongoing price pressure and market volatility. Outlook remains cautiously optimistic for organic growth by year-end, with Americas leading recovery and EMEA still lagging.
Azelis Group NV Earnings Call Transcript: Q1 2024
Azelis Group NV Earnings Call Transcript: H2 2023
Azelis Group NV Earnings Call Transcript: Q3 2023
Azelis Group NV Earnings Call Transcript: H1 2023
Azelis Group NV Earnings Call Transcript: Q1 2023
Azelis Group NV: FY2022 Results: Strong Momentum Drives 70% Growth in Adjusted EBITA
ANTWERP, Belgium--(BUSINESS WIRE)--Regulatory News: Azelis Group NV (Brussels:AZE): (in millions of €) 2022 2021 Reported Change Constant Currency Revenue 4,109.1 2,827.3 45.3% 40.4% Gross Profit 960....